Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome
Article first published online: 3 SEP 2012
© 2012 BJU International
Volume 111, Issue 4, pages 638–646, April 2013
How to Cite
Shie, J.-H., Liu, H.-T., Wang, Y.-S. and Kuo, H.-C. (2013), Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. BJU International, 111: 638–646. doi: 10.1111/j.1464-410X.2012.11466.x
- Issue published online: 2 APR 2013
- Article first published online: 3 SEP 2012
- interstitial cystitis;
- urothelial dysfunction;
- botulinum toxin A
What's known on the subject? and What does the study add?
- A single set of botulinum toxin A (BoNT-A) injections relieves clinical symptoms of interstitial cystitis/bladder pain syndrome (IC/BPS), but lacks long-term effect. An inadequate anti-inflammatory effect is likely to cause treatment failure.
- The study shows that chronic inflammation and apoptotic signalling molecules are significantly reduced after repeated intravesical BoNT-A injection in patients with IC/BPS. It also shows that repeated BoNT-A injections are necessary to achieve greater success in the treatment of IC/BPS.
- To investigate the mechanisms of action of botulinum toxin A (BoNT-A) treatment on interstitial cystitis/bladder pain syndrome (IC/BPS).
Patients and Methods
- A total of 23 women with IC/BPS who received single intravesical BoNT-A injection were studied. Among them, 11 received three repeated injections every 6 months to improve their symptoms.
- Bladder biopsy was obtained before each BoNT-A injection and the clinical symptoms and urodynamic variables were recorded.
- Immunohistochemical (IHC) staining for TUNEL and mast cell activity, and western blotting analysis of tryptase, cytokines, Bax and phospho-p38 (p-p38) were carried out. We compared the clinical results and IHC data among baseline, single or repeated BoNT-A treatments.
- Single BoNT-A injection improved clinical symptoms, pain score and daytime urinary frequency.
- Mast cell activity and apoptotic cell count did not decrease significantly, while Bax and p-p38, but not tryptase, decreased significantly after a single BoNT-A injection.
- The 11 patients who received three repeated BoNT-A injections had significantly lower pain scores than the remaining patients (mean [SD]: 5.80 [2.27] vs. 3.03 [2.30], P = 0), glomerulation degree (mean [SD]: 1.80 [1.06] vs. 1.20 [1.06], P = 0.026) and global response scores (mean [SD]: 0.30 [0.92] vs. 1.20 [1.06], P = 0) after treatment.
- Tryptase, Bax, p-p38 and apoptotic cell counts all decreased significantly.
- 25-kD synaptosomal-associated protein also decreased after BoNT-A treatments, which confirmed the therapeutic effect of repeated BoNT-A injections.
- Chronic inflammation and apoptotic signalling molecules were significantly reduced after repeated BoNT-A injections in patients with IC/BPS.
- The IHC improvement was associated with clinical symptom improvement.
- Repeated BoNT-A injections are necessary to achieve a greater success rate in the treatment of IC/BPS.